Monoclonal antibodies in immune and inflammatory diseases

被引：42

作者：

Andreakos, E ^{[1
]}

Taylor, PC ^{[1
]}

Feldmann, M ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Fac Med, Kennedy Inst, Div Rheumatol, London W6 8LH, England

来源：

CURRENT OPINION IN BIOTECHNOLOGY | 2002年 / 13卷 / 06期

基金：

英国惠康基金;

关键词：

D O I：

10.1016/S0958-1669(02)00355-5

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

The era of monoclonal antibody-based therapeutics has arrived. Monoclonal antibodies of high quality targeting almost any antigen can now be engineered and manufactured in large quantities. In the clinic, monoclonal antibodies are proving to be safe and effective for the treatment of a wide range of diseases including rheumatoid arthritis, Crohn's disease, spondyloarthropathies, psoriasis and allograft rejection.

引用

页码：615 / 620

页数：6

共 73 条

[1] CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
Abrams, JR
Lebwohl, MG
Guzzo, CA
Jegasothy, BV
Goldfarb, MT
Goffe, BS
Menter, A
Lowe, NJ
Krueger, G
Brown, MJ
Weiner, RS
Birkhofer, MJ
Warner, GL
Berry, KK
Linsley, PS
Krueger, JG
Ochs, HD
Kelley, SL
Kang, SW
[J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (09) : 1243 - 1252
[2] Cytokines and anti-cytokine biologicals in autoimmunity: present and future
Andreakos, ET
Foxwell, BM
Brennan, FM
Maini, RN
Feldmann, M
[J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (4-5) : 299 - 313
[3] Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis
Baert, FJ
D'Haens, GR
Peeters, M
Hiele, MI
Schaible, TF
Shealy, D
Geboes, K
Rutgeerts, PJ
[J]. GASTROENTEROLOGY, 1999, 116 (01) : 22 - 28
[4] Effects of treatment with a fully human anti-tumour necrosis factor α monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFα in patients with rheumatoid arthritis
Barrera, P
Joosten, LAB
den Broeder, AA
van de Putte, LBA
van Riel, PLCM
van den Berg, WB
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (07) : 660 - 669
[5] Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody.
Beniaminovitz, A
Itescu, S
Lietz, K
Donovan, M
Burke, EM
Groff, BD
Edwards, N
Mancini, DM
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (09) : 613 - 619
[6] Brandt J, 2002, J RHEUMATOL, V29, P118
[7] Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial
Braun, J
Brandt, J
Listing, J
Zink, A
Alten, R
Golder, W
Gromica-Ihle, E
Kellner, H
Krause, A
Schneider, M
Sörensen, H
Zeidler, H
Thriene, W
Sieper, J
[J]. LANCET, 2002, 359 (9313) : 1187 - 1193
[8] Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO
[9] 2-2
[10] Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
Chaudhari, U
Romano, P
Mulcahy, LD
Dooley, LT
Baker, DG
Gottlieb, AB
[J]. LANCET, 2001, 357 (9271) : 1842 - 1847

← 1 2 3 4 5 6 7 8 →